{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:46:16Z","timestamp":1787499976462,"version":"build-2736575974"},"reference-count":129,"publisher":"Oxford University Press (OUP)","issue":"Supplement_4","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bacterial skin and soft tissue infections are among the most common bacterial infections and constitute a major burden for patients and healthcare systems. Care is complicated by the variety of potential pathogens, some with resistance to previously effective antimicrobial agents, the wide spectrum of clinical presentations and the risk of progression to life-threatening forms. More-efficient care pathways are needed that can reduce hospital admissions and length of stay, while maintaining a high quality of care and adhering to antimicrobial stewardship principles. Several agents approved recently for treating acute bacterial skin and skin structure infections have characteristics that meet these requirements. We address the clinical and pharmacological characteristics of the fourth-generation fluoroquinolone delafloxacin, and the long-acting lipoglycopeptide agents dalbavancin and oritavancin.<\/jats:p>","DOI":"10.1093\/jac\/dkab351","type":"journal-article","created":{"date-parts":[[2021,9,30]],"date-time":"2021-09-30T15:13:33Z","timestamp":1633014813000},"page":"iv9-iv22","source":"Crossref","is-referenced-by-count":11,"title":["Current and future options for treating complicated skin and soft tissue infections: focus on fluoroquinolones and long-acting lipoglycopeptide antibiotics"],"prefix":"10.1093","volume":"76","author":[{"given":"Christian","family":"Eckmann","sequence":"first","affiliation":[{"name":"Department of General, Visceral and Thoracic Surgery, Klinikum Hannoversch-Muenden, Goettingen University, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7121-3623","authenticated-orcid":false,"given":"Paul M","family":"Tulkens","sequence":"additional","affiliation":[{"name":"Cellular and Molecular Pharmacology, Louvain Drug Research Institute, Universit\u00e9 catholique de Louvain (UCLouvain), Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,11,21]]},"reference":[{"key":"2021120104000556400_dkab351-B1","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.3201\/eid1509.081228","article-title":"Trends in US hospital admissions for skin and soft tissue infections","volume":"15","author":"Edelsberg","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"2021120104000556400_dkab351-B2","doi-asserted-by":"crossref","first-page":"e0143276","DOI":"10.1371\/journal.pone.0143276","article-title":"Rising United States hospital admissions for acute bacterial skin and skin structure infections: recent trends and economic impact","volume":"10","author":"Kaye","year":"2015","journal-title":"PLoS One"},{"key":"2021120104000556400_dkab351-B3","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1471-2334-10-151","article-title":"Skin and soft tissue infections in hospitalized and critically ill patients: a nationwide population-based study","volume":"10","author":"Shen","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2021120104000556400_dkab351-B4","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/1471-2334-13-252","article-title":"Incidence, microbiology, and patient characteristics of skin and soft-tissue infections in a U.S. population: a retrospective population-based study","volume":"13","author":"Ray","year":"2013","journal-title":"BMC Infect Dis"},{"key":"2021120104000556400_dkab351-B5","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/QCO.0000000000000239","article-title":"Epidemiology and microbiology of skin and soft tissue infections","volume":"29","author":"Esposito","year":"2016","journal-title":"Curr Opin Infect Dis"},{"key":"2021120104000556400_dkab351-B6","doi-asserted-by":"crossref","first-page":"E377","DOI":"10.1111\/1469-0691.12235","article-title":"Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010-2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study","volume":"19","author":"Garau","year":"2013","journal-title":"Clin Microbiol Infect"},{"key":"2021120104000556400_dkab351-B7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1749-7922-9-57","article-title":"World society of emergency surgery (WSES) guidelines for management of skin and soft tissue infections","volume":"9","author":"Sartelli","year":"2014","journal-title":"World J Emerg Surg"},{"key":"2021120104000556400_dkab351-B8","doi-asserted-by":"crossref","first-page":"e10\u201352","DOI":"10.1093\/cid\/ciu444","article-title":"Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America","volume":"59","author":"Stevens","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13017-018-0219-9","article-title":"2018 WSES\/SIS-E consensus conference: recommendations for the management of skin and soft-tissue infections","volume":"13","author":"Sartelli","year":"2018","journal-title":"World J Emerg Surg"},{"key":"2021120104000556400_dkab351-B10","first-page":"ii37","article-title":"Complicated infections of skin and skin structures: when the infection is more than skin deep","volume":"53 Suppl 2","author":"DiNubile","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B11","first-page":"iii35","article-title":"Complicated skin and soft tissue infection","volume":"65 Suppl 3","author":"Dryden","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B12","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1080\/21548331.2018.1506673","article-title":"Economic burden of hospital admissions for patients with acute bacterial skin and skin structure infections in the United States","volume":"46","author":"Keyloun","year":"2018","journal-title":"Hosp Pract (1995)"},{"key":"2021120104000556400_dkab351-B13","year":"2013"},{"key":"2021120104000556400_dkab351-B14","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ijantimicag.2016.04.023","article-title":"Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe","volume":"48","author":"Nathwani","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2021120104000556400_dkab351-B15","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/cid\/ciw750","article-title":"Early clinical response as a predictor of late treatment success in patients with acute bacterial skin and skin structure infections: retrospective analysis of 2 randomized controlled trials","volume":"64","author":"Nathwani","year":"2017","journal-title":"Clinid"},{"key":"2021120104000556400_dkab351-B16","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1093\/cid\/ciw463","article-title":"Early response in cellulitis: a prospective study of dynamics and predictors","volume":"63","author":"Bruun","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B17","year":"2019"},{"key":"2021120104000556400_dkab351-B18","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2018.11.013","article-title":"Frequency and antimicrobial susceptibility of bacterial isolates from patients hospitalised with community-acquired skin and skin-structure infection in Europe, Asia and Latin America","volume":"17","author":"Sader","year":"2019","journal-title":"J Glob Antimicrob Resist"},{"key":"2021120104000556400_dkab351-B19","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1086\/648083","article-title":"Epidemiology and Outcomes of Hospitalizations with Complicated Skin and Skin-Structure Infections: implications of Healthcare-Associated Infection Risk Factors","volume":"30","author":"Zilberberg","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2021120104000556400_dkab351-B20","year":"2020"},{"key":"2021120104000556400_dkab351-B21","year":"2018"},{"key":"2021120104000556400_dkab351-B22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/S1473-3099(18)30605-4","article-title":"Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis","volume":"19","author":"Cassini","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021120104000556400_dkab351-B23","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2021120104000556400_dkab351-B24","doi-asserted-by":"crossref","first-page":"E10596","DOI":"10.1073\/pnas.1702472114","article-title":"Origin, evolution, and global transmission of community-acquired Staphylococcus aureus ST8","volume":"114","author":"Strau\u00df","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2021120104000556400_dkab351-B25","first-page":"7","article-title":"Molecular epidemiology of the community-associated methicillin-resistant staphylococcus aureus clones: a synthetic review","volume":"91","author":"Junie","year":"2018","journal-title":"Clujul Med"},{"key":"2021120104000556400_dkab351-B26","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cmi.2018.09.023","article-title":"Import of community-associated, methicillin-resistant Staphylococcus aureus to Europe through skin and soft-tissue infection in intercontinental travellers, 2011-2016","volume":"25","author":"Nurjadi","year":"2019","journal-title":"Clin Microbiol Infect"},{"key":"2021120104000556400_dkab351-B27","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.annemergmed.2007.12.004","article-title":"Increased US emergency department visits for skin and soft tissue infections, and changes in antibiotic choices, during the emergence of community-associated methicillin-resistant Staphylococcus aureus","volume":"51","author":"Pallin","year":"2008","journal-title":"Ann Emerg Med"},{"key":"2021120104000556400_dkab351-B28","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.idc.2015.05.007","article-title":"Prevention of Recurrent Staphylococcal Skin Infections","volume":"29","author":"Creech","year":"2015","journal-title":"Infect Dis Clin North Am"},{"key":"2021120104000556400_dkab351-B29","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ijmm.2017.11.009","article-title":"Inside job: staphylococcus aureus host-pathogen interactions","volume":"308","author":"Horn","year":"2018","journal-title":"Int J Med Microbiol"},{"key":"2021120104000556400_dkab351-B30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tim.2008.11.005","article-title":"Staphylococcus aureus: new evidence for intracellular persistence","volume":"17","author":"Garzoni","year":"2009","journal-title":"Trends Microbiol"},{"key":"2021120104000556400_dkab351-B31","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/bies.201400080","article-title":"Staphylococcus aureus chronic and relapsing infections: evidence of a role for persister cells: an investigation of persister cells, their formation and their role in S. aureus disease","volume":"36","author":"Conlon","year":"2014","journal-title":"Bioessays"},{"key":"2021120104000556400_dkab351-B32","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41467-020-15966-7","article-title":"Intracellular Staphylococcus aureus persisters upon antibiotic exposure","volume":"11","author":"Peyrusson","year":"2020","journal-title":"Nat Commun"},{"key":"2021120104000556400_dkab351-B33","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1093\/jac\/dkq362","article-title":"Severity assessment of skin and soft tissue infections: cohort study of management and outcomes for hospitalized patients","volume":"66","author":"Marwick","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B34","doi-asserted-by":"crossref","first-page":"642","DOI":"10.5811\/westjem.2015.7.26213","article-title":"Treatment Failure Outcomes for Emergency Department Patients with Skin and Soft Tissue Infections","volume":"16","author":"May","year":"2015","journal-title":"West J Emerg Med"},{"key":"2021120104000556400_dkab351-B35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1002\/jhm.713","article-title":"Hospitalizations with healthcare-associated complicated skin and skin structure infections: impact of inappropriate empiric therapy on outcomes","volume":"5","author":"Zilberberg","year":"2010","journal-title":"J Hosp Med"},{"key":"2021120104000556400_dkab351-B36","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ajem.2012.07.024","article-title":"Different impact of the appropriateness of empirical antibiotics for bacteremia among younger adults and the elderly in the ED","volume":"31","author":"Lee","year":"2013","journal-title":"Am J Emerg Med"},{"key":"2021120104000556400_dkab351-B37","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1128\/JCM.05817-11","article-title":"Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients","volume":"50","author":"Zervos","year":"2012","journal-title":"J Clin Microbiol"},{"key":"2021120104000556400_dkab351-B38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.diagmicrobio.2014.02.013","article-title":"Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study","volume":"79","author":"Lipsky","year":"2014","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021120104000556400_dkab351-B39","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.ijmm.2013.02.005","article-title":"Hospital-associated MRSA and antibiotic resistance-what have we learned from genomics?","volume":"303","author":"Lindsay","year":"2013","journal-title":"Int J Med Microbiol"},{"key":"2021120104000556400_dkab351-B40","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ijantimicag.2007.07.011","article-title":"Reduced glycopeptide susceptibility in methicillin-resistant Staphylococcus aureus (MRSA)","volume":"30","author":"Appelbaum","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"2021120104000556400_dkab351-B41","doi-asserted-by":"crossref","first-page":"719","DOI":"10.3111\/13696998.2014.940423","article-title":"Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study","volume":"17","author":"Ostermann","year":"2014","journal-title":"J Med Econ"},{"key":"2021120104000556400_dkab351-B42","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12879-016-2067-0","article-title":"Appropriateness of antibiotic management of uncomplicated skin and soft tissue infections in hospitalized adult patients","volume":"16","author":"Walsh","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2021120104000556400_dkab351-B43","doi-asserted-by":"crossref","first-page":"ofx188","DOI":"10.1093\/ofid\/ofx188","article-title":"Guidelines vs actual management of skin and soft tissue infections in the emergency department","volume":"5","author":"Kamath","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B44","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1186\/s13104-019-4849-0","article-title":"A trend in prevalence of antimicrobial use and appropriateness of antimicrobial therapy in an acute care hospital from 2018 to 2019: repeated prevalence surveys in Japan","volume":"12","author":"Komagamine","year":"2019","journal-title":"BMC Res Notes"},{"key":"2021120104000556400_dkab351-B45","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11845-019-02065-w","article-title":"Over-admission and over-treatment of patients with cellulitis: a 5-year audit against international guidelines","volume":"189","author":"Kiely","year":"2020","journal-title":"Ir J Med Sci"},{"key":"2021120104000556400_dkab351-B46","doi-asserted-by":"crossref","first-page":"ofz554","DOI":"10.1093\/ofid\/ofz554","article-title":"Inpatient management of uncomplicated skin and soft tissue infections in 34 Veterans Affairs Medical Centers: a medication use evaluation","volume":"7","author":"Sutton","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B47","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1080\/14740338.2019.1621288","article-title":"The safety of treatment options for acute bacterial skin and skin structure infections","volume":"18","author":"Bassetti","year":"2019","journal-title":"Expert Opin Drug Saf"},{"key":"2021120104000556400_dkab351-B48"},{"key":"2021120104000556400_dkab351-B49"},{"key":"2021120104000556400_dkab351-B50","doi-asserted-by":"crossref","first-page":"e0206893","DOI":"10.1371\/journal.pone.0206893","article-title":"Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012","volume":"13","author":"Tun","year":"2018","journal-title":"PLoS One"},{"key":"2021120104000556400_dkab351-B51","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.annemergmed.2018.09.020","article-title":"Identification of clinical characteristics associated with high-level care among patients with skin and soft tissue infections","volume":"73","author":"Mower","year":"2019","journal-title":"Ann Emerg Med"},{"key":"2021120104000556400_dkab351-B52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1155\/2008\/846453","article-title":"Bacterial skin and soft tissue infections in adults: a review of their epidemiology, pathogenesis, diagnosis, treatment and site of care","volume":"19","author":"Ki","year":"2008","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2021120104000556400_dkab351-B53","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B54","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/jac\/dkp343","article-title":"Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective","volume":"64","author":"Chapman","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B55","doi-asserted-by":"crossref","first-page":"e033367","DOI":"10.1136\/bmjopen-2019-033367","article-title":"Modelling the annual NHS costs and outcomes attributable to healthcare-associated infections in England","volume":"10","author":"Guest","year":"2020","journal-title":"BMJ Open"},{"key":"2021120104000556400_dkab351-B56","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/j.ajem.2016.04.022","article-title":"Intravenous home infusion therapy instituted from a 24-hour clinical decision unit for patients with cellulitis","volume":"34","author":"Rentala","year":"2016","journal-title":"Am J Emerg Med"},{"key":"2021120104000556400_dkab351-B57","doi-asserted-by":"crossref","first-page":"160","DOI":"10.7861\/clinmedicine.18-2-160","article-title":"Diagnosis and management of cellulitis","volume":"18","author":"Sullivan","year":"2018","journal-title":"Clin Med (Lond)"},{"key":"2021120104000556400_dkab351-B58","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2147\/IJGM.S230054","article-title":"Out of hospital and in hospital management of cellulitis requiring intravenous therapy","volume":"12","author":"Ong","year":"2019","journal-title":"Int J Gen Med"},{"key":"2021120104000556400_dkab351-B59","doi-asserted-by":"crossref","first-page":"3125","DOI":"10.1093\/jac\/dkz343","article-title":"Outpatient parenteral antimicrobial therapy: updated recommendations from the UK","volume":"74","author":"Chapman","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B60","doi-asserted-by":"crossref","first-page":"e1\u201335","DOI":"10.1093\/cid\/ciy867","article-title":"2018 infectious diseases society of America clinical practice guideline for the management of outpatient parenteral antimicrobial therapy","volume":"68","author":"Norris","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B61","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.cmi.2015.03.023","article-title":"Implementing criteria-based early switch\/early discharge programmes: a European perspective","volume":"21 Suppl 2","author":"Nathwani","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2021120104000556400_dkab351-B62","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijantimicag.2014.04.007","article-title":"Antibiotic treatment patterns across Europe in patients with complicated skin and soft-tissue infections due to meticillin-resistant Staphylococcus aureus: a plea for implementation of early switch and early discharge criteria","volume":"44","author":"Eckmann","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2021120104000556400_dkab351-B63","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1002\/phar.2389","article-title":"Advantages of outpatient treatment with long-acting lipoglycopeptides for serious gram-positive infections: a review","volume":"40","author":"Krsak","year":"2020","journal-title":"Pharmacother J Hum Pharmacol Drug Ther"},{"key":"2021120104000556400_dkab351-B64","doi-asserted-by":"crossref","first-page":"e00772-17","DOI":"10.1128\/AAC.00772-17","article-title":"In Vitro activity of delafloxacin and microbiological response against fluoroquinolone-susceptible and nonsusceptible Staphylococcus aureus isolates from two phase 3 studies of acute bacterial skin and skin structure infections","volume":"61","author":"McCurdy","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B65","doi-asserted-by":"crossref","first-page":"e02609-16","DOI":"10.1128\/AAC.02609-16","article-title":"In Vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014","volume":"61","author":"Pfaller","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B66","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1128\/AAC.01201-10","article-title":"Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus","volume":"55","author":"Lemaire","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B67","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.2217\/fmb.15.39","article-title":"Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy","volume":"10","author":"Van Bambeke","year":"2015","journal-title":"Future Microbiol"},{"key":"2021120104000556400_dkab351-B68","doi-asserted-by":"crossref","first-page":"881","DOI":"10.2147\/DDDT.S106071","article-title":"Delafloxacin: design, development and potential place in therapy","volume":"11","author":"Candel","year":"2017","journal-title":"Drug Des Devel Ther"},{"key":"2021120104000556400_dkab351-B69","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1093\/jac\/dkx543","article-title":"Clinical review of delafloxacin: a novel anionic fluoroquinolone","volume":"73","author":"Mogle","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B70","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1086\/314056","article-title":"Mechanisms of action and resistance of older and newer fluoroquinolones","volume":"31 Suppl 2","author":"Hooper","year":"2000","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B71","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1093\/jac\/dks307","article-title":"Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization","volume":"67","author":"Remy","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B72"},{"key":"2021120104000556400_dkab351-B73"},{"key":"2021120104000556400_dkab351-B74","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1093\/jac\/dkx329","article-title":"Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study","volume":"72","author":"Pullman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B75","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/cid\/ciy165","article-title":"A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study","volume":"67","author":"O\u2019Riordan","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B76","doi-asserted-by":"crossref","first-page":"S223","DOI":"10.1093\/cid\/ciz006","article-title":"Analysis of pooled phase III efficacy data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Giordano","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B77","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jgar.2020.09.027","article-title":"Update on the activity of delafloxacin against acute bacterial skin and skin-structure infection isolates from European hospitals (2014-2019)","volume":"23","author":"Shortridge","year":"2020","journal-title":"J Glob Antimicrob Resist"},{"key":"2021120104000556400_dkab351-B78","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/cid\/ciz787","article-title":"Emergence of delafloxacin-resistant Staphylococcus aureus in Brooklyn, New York","volume":"70","author":"Iregui","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B79","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.1086\/428055","article-title":"Antimicrobial safety: focus on fluoroquinolones","volume":"41 Suppl 2","author":"Owens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B80","doi-asserted-by":"crossref","first-page":"ofy220","DOI":"10.1093\/ofid\/ofy220","article-title":"Safety of delafloxacin: focus on adverse events of special interest","volume":"5","author":"Lodise","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B81"},{"key":"2021120104000556400_dkab351-B82","doi-asserted-by":"crossref","first-page":"S233","DOI":"10.1093\/cid\/ciy1080","article-title":"Analysis of pooled phase 3 safety data for delafloxacin in acute bacterial skin and skin structure infections","volume":"68","author":"Bassetti","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B83","first-page":"ofz514","article-title":"A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP)","volume":"7","author":"Horcajada","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B84","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1128\/AAC.04813-14","article-title":"A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization","volume":"59","author":"Litwin","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B85","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1128\/AAC.03482-14","article-title":"Comparison of the antibiotic activities of Daptomycin, Vancomycin, and the investigational Fluoroquinolone Delafloxacin against biofilms from Staphylococcus aureus clinical isolates","volume":"58","author":"Siala","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1086\/527392","article-title":"Vancomycin-resistant Staphylococcus aureus in the United States, 2002-2006","volume":"46","author":"Sievert","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B87","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1128\/CMR.00042-09","article-title":"Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications","volume":"23","author":"Howden","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"2021120104000556400_dkab351-B88","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1016\/j.bbamem.2009.05.003","article-title":"Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: effect on membrane permeability and nanoscale lipid membrane organization","volume":"1788","author":"Domenech","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2021120104000556400_dkab351-B89","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.bbamem.2010.06.011","article-title":"Interactions of oritavancin, a new semi-synthetic lipoglycopeptide, with lipids extracted from Staphylococcus aureus","volume":"1798","author":"Domenech","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"2021120104000556400_dkab351-B90","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1128\/AAC.50.3.841-851.2006","article-title":"Pharmacodynamic evaluation of the intracellular activities of antibiotics against Staphylococcus aureus in a model of THP-1 macrophages","volume":"50","author":"Barcia-Macay","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B91","doi-asserted-by":"crossref","first-page":"4342","DOI":"10.1128\/AAC.00169-16","article-title":"Comparative In Vitro Activities of Oritavancin, Dalbavancin, and Vancomycin against Methicillin-Resistant Staphylococcus aureus Isolates in a Nondividing State","volume":"60","author":"Belley","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B92","first-page":"740","article-title":"Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics and clinical efficacy","volume":"7","author":"Van Bambeke","year":"2006","journal-title":"Curr Opin Investig Drugs"},{"key":"2021120104000556400_dkab351-B93","doi-asserted-by":"crossref","first-page":"2723","DOI":"10.1021\/acs.biochem.8b00187","article-title":"Oritavancin retains a high affinity for a vancomycin-resistant cell-wall precursor via its bivalent motifs of interaction","volume":"57","author":"Bowden","year":"2018","journal-title":"Biochemistry"},{"key":"2021120104000556400_dkab351-B94","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1007\/s40265-015-0505-8","article-title":"Lipoglycopeptide antibacterial agents in gram-positive infections: a comparative review","volume":"75","author":"Van Bambeke","year":"2015","journal-title":"Drugs"},{"key":"2021120104000556400_dkab351-B95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0213-005X(17)30029-0","article-title":"[Antimicrobial spectrum of dalbavancin. Mechanism of action and in vitro activity against Gram-positive microorganisms]","volume":"35","author":"Cercenado","year":"2017","journal-title":"Enferm Infecc Microbiol Clin"},{"key":"2021120104000556400_dkab351-B96","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1128\/AAC.48.8.2853-2860.2004","article-title":"Cellular pharmacokinetics and pharmacodynamics of the glycopeptide antibiotic oritavancin (LY333328) in a model of J774 mouse macrophages","volume":"48","author":"Van Bambeke","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B97","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jmb.2008.01.031","article-title":"Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus","volume":"377","author":"Kim","year":"2008","journal-title":"J Mol Biol"},{"key":"2021120104000556400_dkab351-B98","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/jac\/dkp126","article-title":"Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium","volume":"63","author":"McKay","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B99","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.1128\/AAC.00760-10","article-title":"Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing","volume":"54","author":"Belley","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1093\/jac\/dks344","article-title":"Activity of oritavancin against methicillin-resistant staphylococci, vancomycin-resistant enterococci and \u03b2-haemolytic streptococci collected from western European countries in 2011","volume":"68","author":"Morrissey","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"2021120104000556400_dkab351-B101","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1128\/AAC.06067-11","article-title":"Oritavancin activity against vancomycin-susceptible and vancomycin-resistant Enterococci with molecularly characterized glycopeptide resistance genes recovered from bacteremic patients, 2009-2010","volume":"56","author":"Mendes","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B102","doi-asserted-by":"crossref","first-page":"10408","DOI":"10.1021\/bi00107a007","article-title":"Molecular basis for vancomycin resistance in Enterococcus faecium BM4147: biosynthesis of a depsipeptide peptidoglycan precursor by vancomycin resistance proteins VanH and VanA","volume":"30","author":"Bugg","year":"1991","journal-title":"Biochemistry"},{"key":"2021120104000556400_dkab351-B103","doi-asserted-by":"crossref","first-page":"5007","DOI":"10.1128\/AAC.00274-15","article-title":"In Vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program","volume":"59","author":"McCurdy","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B104","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.diagmicrobio.2018.01.029","article-title":"Oritavancin in vitro activity against gram-positive organisms from European and United States medical centers: results from the SENTRY Antimicrobial Surveillance Program for 2010-2014","volume":"91","author":"Pfaller","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2021120104000556400_dkab351-B105","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1128\/AAC.00197-09","article-title":"Impact of human serum albumin on oritavancin in vitro activity against enterococci","volume":"53","author":"McKay","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B106","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1128\/AAC.01264-06","article-title":"In vivo pharmacodynamic activity of the glycopeptide dalbavancin","volume":"51","author":"Andes","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B107","doi-asserted-by":"crossref","first-page":"e01265-17","DOI":"10.1128\/AAC.01265-17","article-title":"Comparative pharmacodynamics of single-dose oritavancin and daily high-dose daptomycin regimens against vancomycin-resistant Enterococcus faecium isolates in an In Vitro pharmacokinetic\/pharmacodynamic model of infection","volume":"61","author":"Belley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B108"},{"key":"2021120104000556400_dkab351-B109"},{"key":"2021120104000556400_dkab351-B110","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"key":"2021120104000556400_dkab351-B111","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s40264-015-0374-9","article-title":"Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies","volume":"39","author":"Dunne","year":"2016","journal-title":"Drug Saf"},{"key":"2021120104000556400_dkab351-B112","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B113"},{"key":"2021120104000556400_dkab351-B114","year":"2019"},{"key":"2021120104000556400_dkab351-B115","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"key":"2021120104000556400_dkab351-B116","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B117","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"Corey","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2021120104000556400_dkab351-B118","doi-asserted-by":"crossref","first-page":"e01919-17","DOI":"10.1128\/AAC.01919-17","article-title":"Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by gram-positive bacteria: summary of safety analysis from the phase 3 SOLO studies","volume":"62","author":"Corey","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021120104000556400_dkab351-B119","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40121-016-0119-9","article-title":"Single-dose oritavancin treatment of acute bacterial skin and skin structure infections: SOLO trial efficacy by Eron severity and management setting","volume":"5","author":"Deck","year":"2016","journal-title":"Infect Dis Ther"},{"key":"2021120104000556400_dkab351-B120","doi-asserted-by":"crossref","first-page":"ofw274","DOI":"10.1093\/ofid\/ofw274","article-title":"Efficacy and safety of oritavancin relative to vancomycin for patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the outpatient setting: results from the SOLO clinical trials","volume":"4","author":"Lodise","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B121","doi-asserted-by":"crossref","first-page":"ofz479","DOI":"10.1093\/ofid\/ofz479","article-title":"The CHROME study, a real-world experience of single- and multiple-dose oritavancin for treatment of gram-positive infections","volume":"6","author":"Redell","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B122","first-page":"752","article-title":"Use of oritavancin in moderate-to-severe ABSSSI patients requiring IV antibiotics: a U.S. payer budget impact analysis","volume":"22","author":"Jensen","year":"2016","journal-title":"J Manag Care Spec Pharm"},{"key":"2021120104000556400_dkab351-B123","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.clinthera.2015.11.014","article-title":"Economic impact of oritavancin for the treatment of acute bacterial skin and skin structure infections in the emergency department or observation setting: cost savings associated with avoidable hospitalizations","volume":"38","author":"Lodise","year":"2016","journal-title":"Clin Ther"},{"key":"2021120104000556400_dkab351-B124","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/23744235.2017.1365169","article-title":"Dalbavancin as a cost effective antibiotic","volume":"50","author":"Nair","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"2021120104000556400_dkab351-B125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s40121-019-00275-4","article-title":"Dalbavancin reduces hospital stay and improves productivity for patients with acute bacterial skin and skin structure infections: the ENHANCE trial","volume":"9","author":"McCarthy","year":"2020","journal-title":"Infect Dis Ther"},{"key":"2021120104000556400_dkab351-B126","doi-asserted-by":"crossref","first-page":"ofz475","DOI":"10.1093\/ofid\/ofz475","article-title":"Comparisons of 30-day admission and 30-day total healthcare costs between patients who were treated with oritavancin or vancomycin for a skin infection in the outpatient setting","volume":"6","author":"Lodise","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2021120104000556400_dkab351-B127","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1007\/s40801-020-00196-6","article-title":"Expediting discharge in hospitalized, adult patients with skin and soft tissue infections who received empiric vancomycin therapy with oritavancin: description of findings from an institutional pathway","volume":"7","author":"Whittaker","year":"2020","journal-title":"Drugs Real World Outcomes"},{"key":"2021120104000556400_dkab351-B128","first-page":"ciaa1732","article-title":"Cost-consequence analysis of single-dose dalbavancin versus standard of care for the treatment of acute bacterial skin and skin structure infections in a multi-site healthcare system","author":"Gonzalez","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021120104000556400_dkab351-B129","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cmi.2017.08.028","article-title":"Newer glycopeptide antibiotics for treatment of complicated skin and soft tissue infections: systematic review, network meta-analysis and cost analysis","volume":"24","author":"Agarwal","year":"2018","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/Supplement_4\/iv9\/41273455\/dkab351.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/76\/Supplement_4\/iv9\/41273455\/dkab351.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T23:32:06Z","timestamp":1638315126000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/Supplement_4\/iv9\/6437937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":129,"journal-issue":{"issue":"Supplement_4","published-online":{"date-parts":[[2021,11,21]]},"published-print":{"date-parts":[[2021,11,22]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkab351","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11,1]]},"published":{"date-parts":[[2021,11,1]]}}}